Clinical Trials

Numerous clinical trials ranging from phase 1 through phase 4—with recruitment statuses including active, recruiting, completed, and withdrawn—evaluate hyaluronidase across conditions such as hematologic malignancies, advanced solid tumors, generalized myasthenia gravis, type 1 diabetes mellitus, scleroderma, and acute dehydration. Sponsored by both pharmaceutical industry entities and academic institutions, these studies primarily assess the enzyme's capacity to facilitate subcutaneous drug administration, improve systemic bioavailability, and alleviate tissue tightness in fibrotic states.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07431827 RECRUITING
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
 2026-03-18 PHASE3
NCT07220187 NOT_YET_RECRUITING
Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
 2026-08-31 PHASE3
NCT07724457 NOT_YET_RECRUITING
Recurrent Burkitt Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements; Refractory Burkitt Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
National Cancer Institute (NCI)
 2026-10-30 PHASE2; PHASE3
NCT07383441 RECRUITING
Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
SWOG Cancer Research Network
 2026-06-05 PHASE3
NCT07605416 RECRUITING
Plasma Cell Leukemia
National Cancer Institute (NCI)
 2027-04-20 PHASE2
NCT07388524 RECRUITING
Lung Non-Small Cell Carcinoma
National Cancer Institute (NCI)
 2027-03-02 PHASE3
NCT06337318 RECRUITING
Classic Follicular Lymphoma; Follicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)
 2024-10-23 PHASE3
NCT07285239 RECRUITING
Multiple Myeloma
PrECOG, LLC.
 2026-09 PHASE3
NCT07110844 RECRUITING
Amyloid Light-chain Amyloidosis
Rajshekhar Chakraborty, MD
 2025-11-07 PHASE2
NCT05561387 RECRUITING
Plasma Cell Myeloma
SWOG Cancer Research Network
 2023-10-12 PHASE3
NCT07247097 NOT_YET_RECRUITING
Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Transplant Ineligible; Newly Diagnosed Multiple Myeloma (NDMM)
Massachusetts General Hospital
 2026-08-01 PHASE2
NCT06022939 RECRUITING
AL Amyloidosis
SWOG Cancer Research Network
 2024-07-01 PHASE3
NCT07042295 SUSPENDED
Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma
National Cancer Institute (NCI)
 2026-03-23 PHASE2
NCT06504394 ACTIVE_NOT_RECRUITING
Classical Hodgkin Lymphoma Recurrent; Classical Hodgkin Lymphoma Refractory; Primary Mediastinal Large B-cell Lymphoma Recurrent; Primary Mediastinal Large B-cell Lymphoma Refractory
Merck Sharp & Dohme LLC
 2024-10-14 PHASE2
NCT07062354 ENROLLING_BY_INVITATION
Head &Amp; Neck Cancer; Head &Amp; Neck Squamous Cell Carcinoma
SWOG Cancer Research Network
 2026-03-25 PHASE2
NCT07734740 NOT_YET_RECRUITING
Dermatochalasis of Upper Eyelid; Blepharoplasty
Prince of Wales Hospital, Shatin, Hong Kong
 2026-08 PHASE3
NCT07485647 RECRUITING
Multiple Myeloma
Eden Biltibo
 2026-04-20 PHASE2
NCT06948084 NOT_YET_RECRUITING
Recurrent Multiple Myeloma; Refractory Multiple Myeloma
National Cancer Institute (NCI)
 2026-08-26 PHASE2
NCT07082270 WITHDRAWN
Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Roswell Park Cancer Institute
 2026-04-01 PHASE1
NCT07705165 NOT_YET_RECRUITING
Osteoarthritis, Knee; Postoperative Edema; Bilateral Total Knee Arthroplasty
Man Soo Kim
 2026-08-01
NCT04566328 RECRUITING
Plasma Cell Myeloma; RISS Stage I Plasma Cell Myeloma; RISS Stage II Plasma Cell Myeloma
ECOG-ACRIN Cancer Research Group
 2021-02-24 PHASE3
NCT06142396 RECRUITING
Multiple Myeloma; Renal Failure
Augusta University
 2024-11-01 EARLY_PHASE1
NCT05256225 RECRUITING
Endometrial Carcinoma; Endometrial Clear Cell Adenocarcinoma; Endometrial Dedifferentiated Carcinoma; Endometrial Endometrioid Adenocarcinoma; Endometrial Mixed Cell Adenocarcinoma; Endometrial Serous Adenocarcinoma; Endometrial Undifferentiated Carcinoma; Uterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
National Cancer Institute (NCI)
 2022-11-16 PHASE3
NCT07697274 NOT_YET_RECRUITING
Systemic Sclerosis; Sclerodactyly
Medical University of South Carolina
 2026-09-01 EARLY_PHASE1
NCT06718413 RECRUITING
Stroke
Johns Hopkins University
 2025-03-28 PHASE2
NCT07742527 NOT_YET_RECRUITING
Multiple Myeloma
GlaxoSmithKline
 2026-10-16 PHASE1
NCT05020860 RECRUITING
Breast Cancer; Breast Neoplasm; Breast Cancer Female; Breast Cancer Invasive; Breast Cancer Stage II; Breast Cancer Stage III; Triple Negative Breast Cancer; Hormone Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Triple Negative Breast Neoplasms; Estrogen Receptor-positive Breast Cancer
Baylor Breast Care Center
 2023-04-18 PHASE2
NCT07161414 RECRUITING
Advanced Solid Tumors
AstraZeneca
 2025-11-25 PHASE1
NCT05289687 RECRUITING
T-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group
 2023-05-25 PHASE2
NCT05418868 RECRUITING
HIV Infections
ViiV Healthcare
 2022-06-14 PHASE1
NCT06622005 RECRUITING
Recurrent Multiple Myeloma; Refractory Multiple Myeloma
Roswell Park Cancer Institute
 2025-04-10 PHASE1
NCT04799275 ACTIVE_NOT_RECRUITING
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma; Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma Activated B-Cell Type; Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation; Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Grade 3b Follicular Lymphoma; HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Intravascular Large B-Cell Lymphoma; Lymphoplasmacytic Lymphoma; Nodular Lymphocyte Predominant B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type; T-Cell/Histiocyte-Rich Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)
 2021-05-20 PHASE2; PHASE3
NCT07085728 ACTIVE_NOT_RECRUITING
Myeloma Multiple
Eastern Cooperative Oncology Group
 2025-08-11 PHASE2
NCT03267433 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
ECOG-ACRIN Cancer Research Group
 2017-11-27 PHASE3
NCT04759586 ACTIVE_NOT_RECRUITING
Primary Mediastinal Large B-Cell Lymphoma
National Cancer Institute (NCI)
 2021-10-05 PHASE3
NCT05340309 ACTIVE_NOT_RECRUITING
Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8
University of Southern California
 2022-12-07 PHASE2
NCT03467867 ACTIVE_NOT_RECRUITING
Chronic Lymphocytic Leukemia
Georgetown University
 2018-04-26 PHASE2
NCT07298746 NOT_YET_RECRUITING
OCTA Changes With Local Anesthesia
Sohag University
 2025-12
NCT05886036 RECRUITING
Nodular Lymphocyte Predominant B-Cell Lymphoma; Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma; Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
National Cancer Institute (NCI)
 2024-01-23 PHASE2
NCT05455697 ACTIVE_NOT_RECRUITING
Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma
University of Washington
 2023-01-26 PHASE1; PHASE2
NCT06169215 ACTIVE_NOT_RECRUITING
Multiple Myeloma
National Cancer Institute (NCI)
 2024-07-23 PHASE2
NCT06398457 RECRUITING
Hematologic Malignancy; Bone Marrow Transplant Rejection; Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS); Acute Lymphoblastic Leukemia (ALL), Adult; Multiple Myeloma; Aplastic Anemia; Lymphoma; Non Hodgkin Lymphoma; Hodgkin Lymphoma; Chronic Myeloid Leukemia; Myelofibrosis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
 2024-09-19 EARLY_PHASE1
NCT07484893 NOT_YET_RECRUITING
Healthy Adult Male
Shanghai Henlius Biotech
 2026-05-14 PHASE1
NCT05300451 ENROLLING_BY_INVITATION
Cardiac Transplant
Barry A. Boilson
 2022-03-31 PHASE2
NCT03500328 ACTIVE_NOT_RECRUITING
Multiple Sclerosis, Relapsing-Remitting
Johns Hopkins University
 2018-05-02
NCT05139225 COMPLETED
Multiple Myeloma
Memorial Sloan Kettering Cancer Center
 2021-10-28 PHASE1
NCT06854380 RECRUITING
Voice and Voice Disorders
Mansoura University
 2026-01-01 EARLY_PHASE1
NCT03306615 ACTIVE_NOT_RECRUITING
Muscle Spasticity
Johns Hopkins University
 2021-10-11 PHASE2
NCT05238831 WITHDRAWN
Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
OHSU Knight Cancer Institute
 2023-01-30 EARLY_PHASE1
NCT06698042 ACTIVE_NOT_RECRUITING
Lung Cancer; Non-Small Cell Lung Cancer
Merck Sharp & Dohme LLC
 2024-11-21 PHASE3
NCT06839391 NOT_YET_RECRUITING
Tab Block Qaulity
Benha University
 2025-03 EARLY_PHASE1
NCT06100874 ACTIVE_NOT_RECRUITING
Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic
Adrienne G. Waks
 2023-11-20 PHASE2
NCT07269613 NOT_YET_RECRUITING
Carpal Tunnel Syndrome (CTS)
Sohag University
 2025-12
NCT07000058 ACTIVE_NOT_RECRUITING
Hand Surgery; Local Infiltration
Misr University for Science and Technology
 2025-06-20 PHASE2; PHASE3
NCT06376214 RECRUITING
Light Chain (AL) Amyloidosis
Nanjing University School of Medicine
 2023-01-01
NCT07436546 COMPLETED
Impacted Third Molar; Impacted Third Molar Tooth; Third Molar Extraction; Third Molar Extraction Surgery
Postgraduate Institute of Dental Sciences Rohtak
 2025-03-23
NCT07141589 RECRUITING
Fentanyl; Ketorolac; Adjuvant; Peribulbar Block; Anterior Segment Surgeries
Cairo University
 2024-08-25
NCT05807048 COMPLETED
Non-small Cell Lung Cancer With STK11/LKB1 Mutation
NYU Langone Health
 2023-06-01 PHASE2
NCT07102771 COMPLETED
Erector Spinae Plane Block, Nephrolithotomy, Hyaluronidase
Kasr El Aini Hospital
 2025-01-01
NCT03281369 TERMINATED
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Hoffmann-La Roche
 2017-10-13 PHASE1; PHASE2
NCT06935266 COMPLETED
Healthy Volunteers
Takeda
 2025-04-22 PHASE1
NCT06046287 WITHDRAWN
Peripheral Neuropathy; Monoclonal Gammopathy of Undetermined Significance
Georgetown University
 2025-09-26 PHASE2
NCT04626791 ACTIVE_NOT_RECRUITING
Mantle Cell Lymphoma
Academic and Community Cancer Research United
 2021-08-03 PHASE2
NCT06980363 NOT_YET_RECRUITING
Local Infiltration
Fayoum University
 2025-06-01 PHASE1
NCT07101016 NOT_YET_RECRUITING
Root End Resection; Periapical Lesion; Single Rooted Teeth
Mariam Hesham Mahmoud Abdelfattah Eissa
 2025-08-01
NCT03590652 TERMINATED
Relapsed/Refractory Multiple Myeloma
University of California, San Diego
 2018-10-17 PHASE2
NCT05730712 COMPLETED
Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
Mayo Clinic
 2024-03-08 PHASE2
NCT06099782 ACTIVE_NOT_RECRUITING
Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma
Merck Sharp & Dohme LLC
 2023-12-26 PHASE2
NCT05498220 TERMINATED
Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
 2023-02-17 PHASE2
NCT06455748 UNKNOWN
Amyloid Light-chain Amyloidosis
Yongyong MA
 2024-03-01
NCT04311606 COMPLETED
Thyroid Eye Disease
Massachusetts Eye and Ear Infirmary
 2020-11-02 PHASE2
NCT06212752 ACTIVE_NOT_RECRUITING
Metastatic Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
 2023-06-13 PHASE3
NCT05995626 COMPLETED
Microstomia; Scleroderma
University of Nebraska
 2024-03-01 EARLY_PHASE1
NCT05004259 COMPLETED
Hemolytic Anemia
Dartmouth-Hitchcock Medical Center
 2022-03-21 PHASE1
NCT06784843 COMPLETED
Cataract
Suez Canal University
 2023-12-01
NCT05722015 ACTIVE_NOT_RECRUITING
Metastatic Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
 2023-02-14 PHASE3
NCT05511428 COMPLETED
Plasma Cell Myeloma
Thomas Jefferson University
 2022-11-08 PHASE4
NCT04447716 ACTIVE_NOT_RECRUITING
Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Follicular Lymphoma; Recurrent Indolent Adult Non-Hodgkin Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Follicular Lymphoma; Refractory Indolent Adult Non-Hodgkin Lymphoma; Refractory Marginal Zone Lymphoma
Thomas Jefferson University
 2020-10-16 PHASE1
NCT06604546 COMPLETED
Healthy
Shanghai Bao Pharmaceuticals Co., Ltd.
 2024-03-28 PHASE3
NCT04659044 TERMINATED
Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma
Academic and Community Cancer Research United
 2021-04-01 PHASE2
NCT05671172 COMPLETED
Pain, Postoperative
Benha University
 2023-05-15
NCT05388669 ACTIVE_NOT_RECRUITING
Advanced or Metastatic Non-small Cell Lung Cancer
Janssen Research & Development, LLC
 2022-08-05 PHASE3
NCT04632992 COMPLETED
Advanced Unresectable or Metastatic Solid Malignancy
Genentech, Inc.
 2021-01-13 PHASE2
NCT04776018 TERMINATED
Relapsed and/or Refractory Multiple Myeloma (RRMM)
Takeda
 2021-04-20 PHASE1; PHASE2
NCT03864419 TERMINATED
Burkitt Lymphoma; KSHV-associated Multicentric Castleman Disease; Diffuse Large B-Cell Lymphoma
Fred Hutchinson Cancer Center
 2019-10-24 PHASE1
NCT05765513 COMPLETED
Periodontitis
Dove Medical Press Ltd
 2023-02-02
NCT05205252 WITHDRAWN
Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy
Epizyme, Inc.
 2021-12-22 PHASE1; PHASE2
NCT02955355 COMPLETED
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Baxalta now part of Shire
 2016-11-14 PHASE3
NCT04484337 COMPLETED
HIV Infections
ViiV Healthcare
 2020-07-31 PHASE1
NCT05291520 COMPLETED
HIV Infections
ViiV Healthcare
 2022-02-23 PHASE1
NCT05922813 COMPLETED
Health, Subjective
BMI Korea
 2022-06-30 PHASE1
NCT05764226 COMPLETED
Chronic Wounds
Nakhia Impex LLC
 2020-07-06
NCT05756595 COMPLETED
Shoulder Pain; Neck Pain; Back Pain; Temporal Pain; Herpes Zoster Pain
Dove Medical Press Ltd
 2020-07-06
NCT04058964 WITHDRAWN
Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8
M.D. Anderson Cancer Center
 2020-02-01 PHASE2
NCT03719131 ACTIVE_NOT_RECRUITING
Cutaneous Melanoma, Stage III; Cutaneous Melanoma, Stage IV; Stage III Melanoma; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Unresectable Melanoma
Emory University
 2019-06-05 PHASE2
NCT03538626 COMPLETED
HIV Antibodies
National Institute of Allergy and Infectious Diseases (NIAID)
 2018-06-21 PHASE1
NCT05374590 Recruiting
Generalized Myasthenia Gravis
argenx
 2022-08-18 Phase 2|Phase 3
NCT05466604 COMPLETED
Edema; Pain; Trismus; Infection, Surgical Site
Hacettepe University
 2019-12-01 PHASE4
NCT04956302 TERMINATED
Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma
Abdullah Khan
 2021-09-27 PHASE1
NCT05059977 COMPLETED
Healthy Volunteers
Takeda
 2021-10-12 PHASE1
NCT04578535 COMPLETED
Healthy Volunteers
Baxalta now part of Shire
 2020-10-27 PHASE1
NCT02549170 COMPLETED
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Baxalta now part of Shire
 2015-12-15 PHASE3
NCT01722916 COMPLETED
Drug Safety
Northwestern University
 2012-10 EARLY_PHASE1
NCT04656704 WITHDRAWN
Microstomia; Scleroderma; CREST Syndrome; Scleromyxedema; Morphea
Brigham and Women's Hospital
 2020-01-01 EARLY_PHASE1
NCT05083663 UNKNOWN
Postoperative Pain
Sohag University
 2021-09-10 PHASE2; PHASE3
NCT04824794 Recruiting
Relapsed or Refractory Multiple Myeloma (RRMM)|Diffuse Large B Cell Lymphoma (DLBCL)|Acute Myeloid Leukemia (AML)
Genmab
 2021-03-09 Phase 1|Phase 2
NCT03660020 UNKNOWN
Postoperative Pain
Assiut University
 2018-05-19
NCT03267940 TERMINATED
Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Intrahepatic; Cholangiocarcinoma, Extrahepatic; Gallbladder Adenocarcinoma
Halozyme Therapeutics
 2017-10-02 PHASE1
NCT02715804 TERMINATED
Pancreatic Ductal Carcinoma
Halozyme Therapeutics
 2016-03-14 PHASE3
NCT02753595 TERMINATED
Metastatic Breast Cancer
Eisai Inc.
 2016-07-13 PHASE1; PHASE2
NCT01959139 COMPLETED
Metastatic Pancreatic Adenocarcinoma
SWOG Cancer Research Network
 2014-01-23 PHASE1; PHASE2
NCT04347733 COMPLETED
Adhesive Capsulitis of Shoulder
Veterans Health Service Medical Center, Seoul, Korea
 2017-05-02 PHASE3
NCT02563548 COMPLETED
NSCLC; Gastric Cancer
Halozyme Therapeutics
 2015-10-22 PHASE1
NCT03481920 TERMINATED
Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer
PH Research, S.L.
 2018-01-10 EARLY_PHASE1
NCT03266406 UNKNOWN
Intraocular Pressure Low
Assiut University
 2017-09
NCT02910882 TERMINATED
Pancreatic Adenocarcinoma Non-resectable
Scripps Health
 2017-01-03 PHASE2
NCT01839487 COMPLETED
Metastatic Pancreatic Cancer
Halozyme Therapeutics
 2013-05-14 PHASE2
NCT03411330 COMPLETED
Addition of Hyalase to Local Anesthetic in Scalp Block
Cairo University
 2017-01-24 EARLY_PHASE1
NCT03436836 COMPLETED
Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery
Cairo University
 2018-01-14
NCT02519452 COMPLETED
Multiple Myeloma
Janssen Research & Development, LLC
 2015-10-22 PHASE1
NCT01987609 COMPLETED
Psoriasis
Tissa Hata, MD
 2015-07 PHASE2
NCT02346370 TERMINATED
Non-small Cell Lung Cancer
Halozyme Therapeutics
 2015-02-10 PHASE1
NCT02667223 TERMINATED
Healthy; Hypercholesterolemia
Pfizer
 2016-02 PHASE1
NCT03243500 COMPLETED
Quality of Ocular Akinesia (Onset and Duration)
Kasr El Aini Hospital
 2015-05-01 PHASE4
NCT02654522 COMPLETED
Dermal Filler
Steve Yoelin M.D. Medical Associates, Inc.
 2016-01 PHASE1
NCT03101033 COMPLETED
Herniated Lumbar Disc
yan lu
 2015-05
NCT01945099 COMPLETED
Type 1 Diabetes
Yale University
 2013-09 EARLY_PHASE1
NCT01928030 TERMINATED
Lymphedema; Malignant Neoplasm
Stanford University
 2013-12 PHASE1; PHASE2
NCT02059694 WITHDRAWN
Upper Eyelid Surgery
Duke University
NCT02199028 COMPLETED
Type 1 Diabetes Mellitus
Stanford University
 2014-07 PHASE1
NCT03662334 COMPLETED
Type 1 Diabetes Mellitus
Halozyme Therapeutics
 2013-10-03 PHASE4
NCT01848990 COMPLETED
Type 1 Diabetes Mellitus
Halozyme Therapeutics
 2013-03 PHASE4
NCT01756157 COMPLETED
Hereditary Angioedema (HAE)
Shire
 2013-02-04 PHASE2
NCT01175213 COMPLETED
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire
 2010-07-28 PHASE3
NCT01485796 COMPLETED
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire
 2011-12-29 PHASE2; PHASE3
NCT01689363 COMPLETED
Allergic Skin Reaction
Amphastar Pharmaceuticals, Inc.
 2012-09 PHASE2
NCT01526733 COMPLETED
Type 1 Diabetes Mellitus
Halozyme Therapeutics
 2011-12 PHASE4
NCT00834704 COMPLETED
Solid Tumor
Halozyme Therapeutics
 2009-02 PHASE1
NCT01275131 COMPLETED
Type 1 Diabetes Mellitus
Halozyme Therapeutics
 2011-01 PHASE1
NCT01426763 COMPLETED
Hereditary Angioedema
Shire
 2011-09-12 PHASE2
NCT01194245 COMPLETED
Diabetes Mellitus, Type 1
Halozyme Therapeutics
 2010-08 PHASE2
NCT01194258 COMPLETED
Diabetes Mellitus, Type II
Halozyme Therapeutics
 2010-08 PHASE2
NCT02293083 COMPLETED
Myofascial Pain Syndrome
Samsung Medical Center
 2010-04
NCT00814320 COMPLETED
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire
 2008-12-18 PHASE3
NCT01120431 WITHDRAWN
Dehydration
Baxter Healthcare Corporation
 2010-05 PHASE4
NCT01116102 TERMINATED
Dehydration
Baxter Healthcare Corporation
 2010-05 PHASE4
NCT00883558 COMPLETED
Diabetes Mellitus, Type 1
Halozyme Therapeutics
 2009-05 PHASE2
NCT00979875 COMPLETED
Healthy
Halozyme Therapeutics
 2009-09 PHASE1
NCT00773175 COMPLETED
Dehydration
Halozyme Therapeutics
 2008-10 PHASE4
NCT00916357 COMPLETED
Diabetes Mellitus, Type 2
Halozyme Therapeutics
 2009-07 PHASE2
NCT00807963 COMPLETED
Risk Factors for or a Diagnosis of Osteoporosis
Halozyme Therapeutics
 2008-12 PHASE1
NCT00803972 COMPLETED
Healthy Volunteers
Halozyme Therapeutics
 2008-11 PHASE1
NCT00318643 COMPLETED
Bladder Cancer
Halozyme Therapeutics
 2006-03-30 PHASE1; PHASE2
NCT00862849 COMPLETED
Diabetes Mellitus
Halozyme Therapeutics
 2009-03 PHASE1
NCT00774800 COMPLETED
Type 1 Diabetes Mellitus
Halozyme Therapeutics
 2008-10 PHASE2
NCT00740727 COMPLETED
Disaster Medicine; Difficult Intravenous Access; Dehydration
Massachusetts General Hospital
 2009-02 PHASE1
NCT00782587 COMPLETED
Superficial Bladder Cancer
Halozyme Therapeutics
 2008-10 PHASE1
NCT00807885 COMPLETED
Dehydration
Baxter Healthcare Corporation
 2008-12 PHASE4
NCT00477152 COMPLETED
Dehydration
Baxter Healthcare Corporation
 2007-08 PHASE4
NCT00705536 COMPLETED
Diabetes Mellitus
Halozyme Therapeutics
 2007-12 PHASE1
NCT00656370 COMPLETED
Healthy
Halozyme Therapeutics
 2007-12 PHASE4
NCT00386386 COMPLETED
Mass Casualty Incident; Dehydration
Massachusetts General Hospital
 2007-05 PHASE3
NCT00782106 COMPLETED
Primary Immunodeficiency Diseases (PID)
Baxalta now part of Shire
 2006-12-04 PHASE1; PHASE2
NCT01719978 COMPLETED
Cardiac Arrhythmias
Mauricio Jose Tornelli
 2007-10 PHASE4
NCT00493220 COMPLETED
Healthy
Baxter Healthcare Corporation
 2007-06 PHASE1
NCT00198471 COMPLETED
Vitreous Detachment; Diabetic Retinopathy
Bausch & Lomb Incorporated
 2005-07 PHASE2
NCT00593281 COMPLETED
Pain
Halozyme Therapeutics
 2006-01 PHASE3
NCT00198549 COMPLETED
Pain
Bausch & Lomb Incorporated
 2004-09 PHASE4
NCT00198484 COMPLETED
Pain
Bausch & Lomb Incorporated
 2004-10 PHASE3
NCT00198458 COMPLETED
Drug Hypersensitivity
Bausch & Lomb Incorporated
 2004-07 PHASE1
NCT00198419 COMPLETED
Drug Hypersensitivity
Bausch & Lomb Incorporated
 2004-03 PHASE1
NCT00198510 COMPLETED
Vitreous Hemorrhage; Diabetic Retinopathy
Bausch & Lomb Incorporated
 1998-11 PHASE3
NCT00198497 COMPLETED
Vitreous Hemorrhage; Diabetic Retinopathy
Bausch & Lomb Incorporated
 1999-06 PHASE3
NCT00000493 COMPLETED
Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Infarction; Myocardial Ischemia
National Heart, Lung, and Blood Institute (NHLBI)
 1977-09 PHASE3
NCT00311519 COMPLETED
Healthy
Halozyme Therapeutics
 2005-11 PHASE4
NCT00369187 COMPLETED
Rheumatoid Arthritis
Halozyme Therapeutics
 2006-07 PHASE4
NCT00435604 COMPLETED
Healthy
Halozyme Therapeutics
 2007-02 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-28)

Check the Hyaluronidase product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Hyaluronidase catalyzes the cleavage of glycosidic bonds within hyaluronic acid, degrading this key structural constituent of the extracellular matrix to transiently reduce interstitial viscosity and elevate tissue permeability. This enzymatic dispersion facilitates the rapid diffusion and systemic absorption of co-administered therapeutics, establishing its therapeutic relevance in subcutaneous drug delivery protocols, rehydration management, and localized extracellular matrix disorders such as scleroderma.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.